<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159638">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01752894</url>
  </required_header>
  <id_info>
    <org_study_id>1-2012-0047</org_study_id>
    <nct_id>NCT01752894</nct_id>
  </id_info>
  <brief_title>DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents Versus Biolimus A9-eluting Stents; DETECT-OCT Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is 1&gt; to compare neointimal stent coverage after OCT-guided vs.
      Angio-guided PCI, 2&gt; to compare neointimal stent coverage at 3 months after EES (Xience
      Prime®) vs N-BES (Nobori®) implantation, and 3&gt; to determine the duration of dual
      antiplatelet therapy by OCT measurement at 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Neointimal coverage</measure>
    <time_frame>at 3 month-OCT after stent implantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Angio-guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Angio-guided PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OCT-guided PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCT-guided PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-BES (Nobori®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-BES (Nobori®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EES (Xience Prime®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EES (Xience Prime®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angio-guided intervention</intervention_name>
    <arm_group_label>Angio-guided PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT-guided intervention</intervention_name>
    <arm_group_label>OCT-guided PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCI with N-BES (Nobori®) under angio-guide or OCT guide</intervention_name>
    <arm_group_label>N-BES (Nobori®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCI with EES (Xience Prime®) under angio-guide or OCT guide</intervention_name>
    <arm_group_label>EES (Xience Prime®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 20 years old

          -  Patients with ischemic heart disease who are considered for coronary
             revascularization with stent implantation.

          -  Significant coronary de novo lesion (stenosis &gt; 70% by quantitative angiographic
             analysis) treated by single DES ≤ 25mm

          -  Reference vessel diameter of 2.5 to 3.5 mm by operator assessment

        Exclusion Criteria:

          -  Complex lesion morphologies such as arota-ostial, unprotected left main, chronic
             total occlusion,    graft, thrombosis, and restenosis

          -  Reference vessel diameter &lt; 2.5 mm or &gt; 4.0mm

          -  Heavy calcified lesions (definite calcified lesions on angiogram)

          -  Lesions requiring 2 or more DES

          -  Primary PCI for STEMI

          -  Contraindication to anti-platelet agents

          -  Treated with any DES within 3 months at other vessel

          -  Creatinine level ≥ 2.0 mg/dL or ESRD

          -  Severe hepatic dysfunction (3 times normal reference values)

          -  Pregnant women or women with potential childbearing

          -  Life expectancy &lt; 1 year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>MYEONG-KI HONG, MD</last_name>
    <phone>82-2-2228-8458</phone>
    <email>MKHONG61@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MYEONG-KI HONG, MD</last_name>
      <phone>82-2-2228-8458</phone>
      <email>MKHONG61@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>December 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
